Seeking Alpha

Access Pharmaceuticals Inc. (ACCP.OB)

()

News & PR
Market Currents

Buzz
Twitter: ACCP.OB

Business Intelligence
Transcripts
Events
Key Developments

Instablog posts on ACCP.OB

Access Pharmaceuticals by Jack Haddad
ACCP's FDA drug Mugard treats mucositis, a side effect of chemotherapy and radiation therapy. It's now sold in Europe, with a global market potential of $5 billion, says Access. The company regained North American rights this summer and hopes to partner with a big drugmaker. Keith Markey... More »
October 3, 2009 • ACCP.OB
Access Pharma (OTC:ACCP): Deep Pipeline, Shallow Valuation by Mike Havrilla
Access Pharma (OTC:ACCP)(ACCP.OB) is an emerging bio-pharmaceutical company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to a treatment for a common side effect of some cancer treatments known as mucositis (painful sores in the mouth and GI... More »
July 14, 2009 • ACCP.OB, AEZS, ALTH
Why MuGard Will Be Successful by Michael Catalin Vlaicu
Access Pharmaceuticals, Inc. (OTC:ACCP) Many investors have raised concerns with regards to Access Pharmaceuticals being on the OTC. Indeed more than half the time companies which are not listed on a major exchange tend to lie, cheat and do just about anything possible in order to stimulate... More »
July 5, 2009 • ACCP.OB
Lixte Biotech (OTC:LIXT): Key 2H09 Catalysts Await by Mike Havrilla
Since I first wrote about Lixte Biotech (OTC:LIXT) at BioMedReports.com in early April, the Company has provided an update on its development-stage cancer drug discovery operations as part of a SEC 10Q filing in mid-May for 1Q09. LIXT.OB was originally founded as a diagnostics company in 2005... More »
June 23, 2009 • CTIC, ACCP.OB, SPPI
Access Pharma: Preparing to Advance Pipeline by Mike Havrilla
Since I last wrote about Access Pharma (OTC:ACCP) two weeks ago as a cancer biotech call option trade, the Company has issued two updates on its clinical development pipeline and two updates for MuGard – which is an oral rinse product for the management of a common side effect of many... More »
June 10, 2009 • ACCP.OB, CTIC
Gaining Momentum - Access Pharmaceuticals (OTC:ACCP) by Michael Catalin Vlaicu
Access Pharmaceuticals (OTC:ACCP), a once struggling and troubled company, Access has put these issues behind them and is emerging as one of the top undervalued players in the BioPharma industry. Not only does this company have products which target a large and extensive market, but they are... More »
June 10, 2009 • ACCP.OB
Access Pharma: A Cancer Biotech Call Option Trade by Mike Havrilla
The cancer biotech space has attracted the interest of investors, traders, and diversified healthcare giants this year with Johnson & Johnson (NYSE: JNJ) announcing a $1B cash tender offer for Cougar Biotech (NASDAQ: CGRB) last week and Roche's (VTX: ROG) (OTC: RHHBY) mega-deal to acquire... More »
May 27, 2009 • ACCP.OB, JNJ, CTIC
Cell Therapeutics Sells $20M in Stock, Warrants by Mike Havrilla
After the market close, Cell Therapeutics (NASDAQ:CTIC) announced the sale of $20M of its common stock at $1.25 per share along with warrant coverage to a single institutional investor. CTIC plans to use $17.8M in cash on hand and/or raised through this sale to pay for its anticipated 'Modified... More »
May 11, 2009 • ACCP.OB, CTIC, VNDA
Access Pharma (OTC:ACCP): Low Valuation, Big Potential by Mike Havrilla
With shares of Cell Therapeutics (NASDAQ:CTIC) staging the most astonishing comeback I have ever witnessed while rising from 8 cents at the time of my original article in early February to as high as $1.85 during intraday trading today and closing at $1.27 – I went in search of another... More »
May 6, 2009 • ACCP.OB, CTIC, SNY

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Access Pharmaceuticals Inc. (ACCP.OB)

Instablog posts on ACCP.OB

Access Pharmaceuticals by Jack Haddad

Access Pharma (OTC:ACCP): Deep Pipeline, Shallow Valuation by Mike Havrilla

Why MuGard Will Be Successful by Michael Catalin Vlaicu

Lixte Biotech (OTC:LIXT): Key 2H09 Catalysts Await by Mike Havrilla

Access Pharma: Preparing to Advance Pipeline by Mike Havrilla

Gaining Momentum - Access Pharmaceuticals (OTC:ACCP) by Michael Catalin Vlaicu

Access Pharma: A Cancer Biotech Call Option Trade by Mike Havrilla

Cell Therapeutics Sells $20M in Stock, Warrants by Mike Havrilla

Access Pharma (OTC:ACCP): Low Valuation, Big Potential by Mike Havrilla

The Seeking Alpha 100

Fastest Climbers

Top Commenters

Top Instabloggers

Top StockTalkers